Dr. Craig M. Walker, MD
Interventional Cardiology (Interventional Cardiology Physician)
Who else practices at this address →
Terrebonne Parish is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 409
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Louisiana State University School of Medicine in New Orleans
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Cardiology Physician primary
LA license 014224 -
Cardiovascular Disease Physician
LA license 014224
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Medical Center Acute New Orleans, LA
- Ochsner Lafayette General Medical Center Lafayette, LA
- Thibodaux Regional Medical Center Thibodaux, LA
- Terrebonne General Medical Center - PArish Houma, LA
Medical groups
- Cardiovascular Institute of the South, LLC (146 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 409
- Services billed
- 4,342
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 7,708 | 51 |
| Established patient office or other outpatient visit, 30-39 minutes | 377 | 208 |
| Blood test, lipids (cholesterol and triglycerides) | 255 | 199 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 250 | 30 |
| Established patient office or other outpatient visit, 20-29 minutes | 250 | 158 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 246 | 171 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 220 | 180 |
| Blood test, basic group of blood chemicals (calcium, total) | 208 | 142 |
| Blood test, comprehensive group of blood chemicals | 167 | 129 |
| Injection of chemical agent into single incompetent vein of leg using ultrasound guidance | 154 | 91 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Houma, LA | 896 |
| Atorvastatin Calcium Other prescribers in Houma, LA | 519 |
| Rosuvastatin Calcium Other prescribers in Houma, LA | 488 |
| Amlodipine Besylate Other prescribers in Houma, LA | 484 |
| Olmesartan Medoxomil Other prescribers in Houma, LA | 363 |
| Alprazolam Other prescribers in Houma, LA | 355 |
| Metoprolol Succinate Other prescribers in Houma, LA | 351 |
| Isosorbide Mononitrate Er (isosorbide mononitrate) Other prescribers in Houma, LA | 288 |
| Hydrochlorothiazide Other prescribers in Houma, LA | 271 |
| Furosemide Other prescribers in Houma, LA | 232 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 31 companies reported 170 payments worth $115,150 in total to this clinician.
| Novo Nordisk Inc | $57,327 |
|---|---|
| Philips North America LLC | $32,982 |
| Angiodynamics, Inc. | $8,680 |
| Bayer HealthCare Pharmaceuticals Inc. | $4,100 |
| Novartis Pharmaceuticals Corporation | $2,921 |
| Asahi Intecc Co., LTD. | $2,265 |
| Asahi Intecc USA, Inc. | $2,252 |
| Cordis US Corp. | $793 |
| Compensation for services other than consulting (speaking, faculty) | $58,420 |
|---|---|
| Consulting Fee | $27,525 |
| Honoraria | $9,800 |
| Long term medical supply or device loan | $7,900 |
| Food and Beverage | $7,594 |
| Travel and Lodging | $3,780 |
| Gift | $98.77 |
| Education | $32.27 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Philips North America LLC Nov 12, 2025 | Consulting Fee IGT Devices Undivided · Medical Device | $8,450 |
| Philips North America LLC Aug 13, 2025 | Honoraria US EQ Undivided · Medical Device | $7,800 |
| Philips North America LLC Mar 5, 2025 | Consulting Fee IGT Devices Undivided · Medical Device | $7,800 |
| Novo Nordisk Inc Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $6,355 |
| Novo Nordisk Inc Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $6,355 |
| Novo Nordisk Inc Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $6,355 |
| Angiodynamics, Inc. Dec 1, 2025 | Long term medical supply or device loan Auryon Laser System 100-120 Vac · CV · in-kind | $5,500 |
| Philips North America LLC Jun 11, 2025 | Consulting Fee IGT Devices Undivided · Medical Device | $5,200 |
| Novo Nordisk Inc May 22, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $5,115 |
| Novo Nordisk Inc May 20, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $5,115 |
All 44 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Angiodynamics, Inc. Dec 31, 2025 | Long term medical supply or device loan VenaCure 1470 Pro · ID · in-kind | $1,200 |
| Angiodynamics, Inc. Dec 31, 2025 | Long term medical supply or device loan VenaCure 1470 Pro · ID · in-kind | $1,200 |
| Asahi Intecc Co., LTD. Dec 29, 2025 | Honoraria | $2,000 |
| Asahi Intecc Co., LTD. Dec 25, 2025 | Gift in-kind | $98.77 |
| Philips North America LLC Dec 18, 2025 | Consulting Fee IGT Devices Undivided · Medical Device | $1,300 |
| Novo Nordisk Inc Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,790 |
| Novo Nordisk Inc Dec 4, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Lafayette, LA · in-kind | $1,157 |
| Angiodynamics, Inc. Dec 1, 2025 | Long term medical supply or device loan Auryon Laser System 100-120 Vac · CV · in-kind | $5,500 |
| Reflow Medical Inc Nov 19, 2025 | Travel and Lodging travel to San Clemente, CA | $72.09 |
| Reflow Medical Inc Nov 19, 2025 | Travel and Lodging travel to San Clemente, CA | $47.28 |
| Novo Nordisk Inc Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $1,240 |
| Philips North America LLC Nov 12, 2025 | Consulting Fee IGT Devices Undivided · Medical Device | $8,450 |
| Novo Nordisk Inc Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $1,240 |
| Cordis US Corp. Sep 26, 2025 | Consulting Fee MYNX CONTROL VENOUS · Cardiology/Vascular Diseases | $175 |
| Novo Nordisk Inc Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $6,355 |
| Novo Nordisk Inc Sep 25, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Houma, LA · in-kind | $13.44 |
| Novo Nordisk Inc Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $4,030 |
| Novo Nordisk Inc Sep 19, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Lafayette, LA · in-kind | $143 |
| Novo Nordisk Inc Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $1,240 |
| Novo Nordisk Inc Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $6,355 |
| Novo Nordisk Inc Aug 21, 2025 | Travel and Lodging Ozempic · Diabetes · travel to New Orleans, LA · in-kind | $1,254 |
| Philips North America LLC Aug 13, 2025 | Honoraria US EQ Undivided · Medical Device | $7,800 |
| Penumbra, Inc. Aug 13, 2025 | Consulting Fee Artemis · Neurosurgery | $225 |
| Asahi Intecc USA, Inc. Jul 14, 2025 | Compensation for services other than consulting (speaking, faculty) Asahi Interventional Radiology Wires · Devices | $2,000 |
| Novo Nordisk Inc Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $4,185 |
| Novo Nordisk Inc Jun 27, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Baton Rouge, LA · in-kind | $114 |
| Novo Nordisk Inc Jun 26, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $1,240 |
| Philips North America LLC Jun 25, 2025 | Consulting Fee IGT Devices Undivided · Medical Device | $500 |
| Novo Nordisk Inc Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $6,355 |
| Novo Nordisk Inc Jun 24, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Thibodaux, LA · in-kind | $20.02 |
| Novartis Pharmaceuticals Corporation Jun 18, 2025 | Consulting Fee LEQVIO · Cardiology/Vascular Diseases | $2,775 |
| Philips North America LLC Jun 11, 2025 | Consulting Fee IGT Devices Undivided · Medical Device | $5,200 |
| Novo Nordisk Inc May 22, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $5,115 |
| Novo Nordisk Inc May 22, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Metairie, LA · in-kind | $804 |
| Novo Nordisk Inc May 20, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $5,115 |
| Novo Nordisk Inc May 20, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Houma, LA · in-kind | $9.59 |
| Novo Nordisk Inc May 8, 2025 | Education Ozempic · Diabetes · in-kind | $32.27 |
| Novo Nordisk Inc Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $4,030 |
| Novo Nordisk Inc Apr 30, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Lafayette, LA · in-kind | $147 |
| Novo Nordisk Inc Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $3,030 |
| Terumo Medical Corporation Mar 26, 2025 | Consulting Fee NAVICROSS · VASCULAR ACCESS | $450 |
| Philips North America LLC Mar 5, 2025 | Consulting Fee IGT Devices Undivided · Medical Device | $7,800 |
| Bayer HealthCare Pharmaceuticals Inc. Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $4,100 |
| Philips North America LLC Jan 29, 2025 | Consulting Fee IGT Devices Undivided · Medical Device | $650 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 7 companies. The companies reported $87,063 in research payments for these studies, mostly to the institutions running them.
- The THOR IDE Study
Philips North America LLC · Recruiting · NCT05916950 - Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
Boston Scientific Corporation · Recruiting · NCT04674969 - AGILITY BDPI-20-010
Bard Peripheral Vascular, Inc. - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - NCT04227899--LIFE-BTK Randomized Controlled Trial
Abbott Laboratories - A prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of peripheral arterial disease: MIMICS-3D-USA
Veryan Medical Incorporated - AMBITION
Angiodynamics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.